HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Despite promise, ‘maximum potential’ of precision medicine yet to be reached
-
- Precision medicine: The genomic signature ‘is the diagnosis’ Razelle Kurzrock, MD
- 2015 Oncology Drugs in the Pipeline
- Does the world need authors or critics, if we have to choose? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Cyramza for mCRC
- FDA grants breakthrough therapy designation to rucaparib for advanced ovarian cancer
- FDA grants breakthrough therapy designation to Xalkori for ROS1-positive NSCLC
- FDA grants fast track status to Cometriq for advanced renal cell carcinoma
- FDA grants fast track status to CRLX101 for mRCC
-
- FDA grants orphan drug designation to Sanguinate for sickle cell disease
- FDA grants orphan drug status to pritumumab for brain cancer
- Apixaban does not increase bleeding in patients with renal insufficiencies
- Benefits of surgical resection for small cell lung cancer remain unclear
- Blood transfusions during transport to trauma center improve survival
- Breast cancer survivors do not face increased chronic disease mortality
- Children with allergies at greater risk for primary immune thrombocytopenia
- Effect of aspirin, NSAIDS on colorectal cancer risk differs by genetic variables
-
- Experts discuss whether shift in Medicare will reduce costs, improve quality of care
- Experts set priorities to improve lymphoma research
- FANG vaccine stalls disease recurrence in ovarian cancer
- FDA panel recommends approval of T-VEC for metastatic melanoma
- Genomic maps could improve pediatric adrenocortical tumor identification, treatment
- Gram-negative infections exhibited higher multidrug resistance among pediatric cancer patients
- HPV-initiated OPSCC associated with longer time to metastasis development
- IMRT, 3D-CRT confer similar patient-reported outcomes in prostate cancer
-
- Metformin may reduce lung cancer risk for nonsmokers with diabetes
- Order of JAK2, TET2 mutations influences clinical features of myeloproliferative neoplasms
- Pathologists concordance rates vary for DCIS, atypia diagnoses
- Pediatric germ cell tumor incidence varied by gender, age; survival high
- Pembrolizumab active in PD-L1–positive NSCLC, superior to ipilimumab in treatment-naive advanced melanoma
- Reduced ischemia time may decrease HCC recurrence after liver transplant
- Respiratory virus infection before HCT increases mortality
- Salpingectomy may reduce risk for ovarian cancer
-
- Some long-term survivors of low-grade glioma experience decline in health-related quality of life
- Surveillance imaging unnecessary for most patients with early-stage Hodgkin's lymphoma
- Trabectedin combination benefits certain patients with advanced ovarian cancer
- Transoral robotic surgery alone acceptable for oropharyngeal cancer
- Tumor location in colorectal cancer may predict survival
- USPSTF: Insufficient evidence to screen for iron deficiency anemia in pregnant women, young children
- Utilization of SLNB alone increased in early-stage breast cancer
- VB-111 plus bevacizumab confers positive interim results in recurrent glioblastoma
-
- Neoadjuvant vs. adjuvant ADT yields similar survival rates for prostate cancer
- Arizona Cancer Coalition elects new chairman
- Cancer center director receives award from Bone Marrow Foundation
- Immunology chairman receives award for cancer research
- Roswell Park Cancer Institute president names leadership team
- Society for Translational Oncology presents Pinedo Prize
- Society of Gynecologic Oncology president begins 1-year term
- SSO meeting spotlights ‘amazing’ progress in surgical oncology Nicholas J. Petrelli, MD, FACS
-
- ACS, Stand Up To Cancer announce lung cancer research initiative
- Benefits of combining targeted therapy, immunotherapy remain unclear
- Breast cancer incidence will increase by 50% by 2030
- Erlotinib, bevacizumab yield negligible outcome in metastatic melanoma
- Greater understanding of resistance mechanisms needed in basal cell carcinoma
- 'Liquid biopsy' leads to earlier detection of NSCLC treatment resistance
- Merkel polyomavirus provides insights into Merkel cell carcinoma
- Metformin may not improve survival in pancreatic cancer
-
- MSLT-I results should impact future clinical trial design in melanoma
- Novel olaparib combination shows activity in ovarian, breast cancers
- Prolonged overnight fasting may reduce breast cancer risk
- SLNB used in patients with thin melanomas prior to guidelines
- Systemic therapy plays role in evolving paradigm for brain metastases
- T-VEC plus ipilimumab appears safe, effective for unresected melanoma